

Tze-Peng Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7473226/publications.pdf>

Version: 2024-02-01

25
papers

789
citations

687363

13
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

1519
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of Fosfomycin in Combination with Nine Antibiotics in Human Plasma and Cation-Adjusted Mueller-Hinton II Broth via LCMS. <i>Antibiotics</i> , 2022, 11, 54.	3.7	2
2	Determining the Development of Persisters in Extensively Drug-Resistant <i>Acinetobacter baumannii</i> upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
3	Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures. <i>Microorganisms</i> , 2020, 8, 1814.	3.6	4
4	Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study. <i>Antibiotics</i> , 2020, 9, 451.	3.7	14
5	Elimination of Extracellular Adenosine Triphosphate for the Rapid Prediction of Quantitative Plate Counts in 24 h Time-Kill Studies against Carbapenem-Resistant Gram-Negative Bacteria. <i>Microorganisms</i> , 2020, 8, 1489.	3.6	1
6	<i>In Vitro</i> Pharmacodynamics of Fosfomycin against Carbapenem-Resistant <i>Enterobacter cloacae</i> and <i>Klebsiella aerogenes</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	3
7	<i>In vitro</i> Pharmacodynamics and PK/PD in Animals. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 105-116.	1.6	7
8	Molecular mechanisms of azole resistance in <i>Candida</i> bloodstream isolates. <i>BMC Infectious Diseases</i> , 2019, 19, 63.	2.9	34
9	Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1591-1596.	2.7	6
10	Rapid Antibiotic Combination Testing for Carbapenem-Resistant Gram-Negative Bacteria within Six Hours Using ATP Bioluminescence. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	10
11	Candidemia in a major regional tertiary referral hospital — epidemiology, practice patterns and outcomes. <i>Antimicrobial Resistance and Infection Control</i> , 2017, 6, 27.	4.1	24
12	Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant <i>Escherichia coli</i> in Time-Kill Studies and in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
13	Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. <i>Microorganisms</i> , 2016, 4, 13.	3.6	26
14	From Bench-Top to Bedside: A Prospective <i>In Vitro</i> Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB). <i>PLoS ONE</i> , 2016, 11, e0158740.	2.5	13
15	Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative <i>Bacillus</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4013-4022.	3.2	24
16	Antimicrobial Cluster Bombs: Silver Nanoclusters Packed with Daptomycin. <i>ACS Nano</i> , 2016, 10, 7934-7942.	14.6	304
17	<i>mcr-1</i> in Multidrug-Resistant <i>bla</i> KPC-2-Producing Clinical Enterobacteriaceae Isolates in Singapore. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6435-6437.	3.2	29
18	<i>In Vitro</i> Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant <i>Enterobacter cloacae</i> with Decreased Susceptibility to Polymyxin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5238-5246.	3.2	14

#	ARTICLE	IF	CITATIONS
19	Intravenous ceftaroline 200mg administered every 8h is safe and adequate for methicillin-resistant <i>Staphylococcus aureus</i> bloodstream infections in end-stage renal failure patients on haemodialysis: a case study. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 720-721.	2.5	2
20	<i>In Vitro</i> Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2515-2524.	3.2	39
21	Extensively drug-resistant <i>Acinetobacter baumannii</i> in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. <i>Antimicrobial Resistance and Infection Control</i> , 2015, 4, 2.	4.1	42
22	In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Singapore. <i>PLoS ONE</i> , 2011, 6, e18485.	2.5	55
23	Effective Antibiotics in Combination against Extreme Drug-Resistant <i>Pseudomonas aeruginosa</i> with Decreased Susceptibility to Polymyxin B. <i>PLoS ONE</i> , 2011, 6, e28177.	2.5	51
24	In vitro activity of various combinations of antimicrobials against carbapenem-resistant <i>Acinetobacter</i> species in Singapore. <i>Journal of Antibiotics</i> , 2009, 62, 675-679.	2.0	27
25	Quantitative Assessment of Combination Antimicrobial Therapy against Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2898-2904.	3.2	31